

4/7/04



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Filing Date	Herewith
				First Named Inventor	Gilbert, Michel, et. al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	019633-000112US

U.S. PATENT DOCUMENTS						
Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CS A	AA	US-5,352,870		10-04-1994	Venot, et al.	
	AB	US-5,374,541		12-20-1994	Wong, et al.	
	AC	US-5,545,553		08-13-1996	Gotschlich	
		US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
CS	AD	WO	92/16640		10-01-1992	The Scripps Research Institute		<input type="checkbox"/>
	AE	WO	96/32491		10-17-1996	Cytel Corp.		<input type="checkbox"/>
	AF	WO	99/49051	A1	09-30-1999	National Research Council of Canada		<input type="checkbox"/>
								<input type="checkbox"/>

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
851	AG	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 241-249 (1994b)		
	AH	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 250-255 (1994c)		
	AI	ASPINALL, et al. " Chemical Structures of the Core Regions of Campylobacter Jejuni Serotypes O:1, O:4, O:23, and O:36 Lipopolysaccharides," European Journal of Biochemistry, Vol. 213, No. 3, pp. 1017-1027, (May 1993)		
	AJ	ASPINALL, et al. "Lipopolysaccharides from Campylobacter Jejuni Associated with Guillain-Barré Syndrome Patients Mimic Human Gangliosides in Structure," Infection and Immunity, Vol. 62, No. 5, pp. 2122-2125, (May 1994)		
	AK	BELUNIS et al., "Biosynthesis of Endotoxin" J. Biol. Chem., 267: 9988-9997 (1992)		
	AL	GAUDINO et al., "A Novel and Efficient Synthesis of Neolacto Series Gangliosides 3'-nLM1 and 6'-nLM1 " J. Am. Chem. Soc., 116: 1149-1150 (1994)		

Examiner Signature	SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER	Date Considered	040706
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1404050 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
Application Number		Filing Date	Herewith
First Named Inventor		Art Unit	Unassigned
Examiner Name		Attorney Docket Number	019633-000112US
Sheet	2	of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
85	AM	GILBERT et al., "Cloning of the Lipooligosaccharide α-2,3-Sialyltransferase from the Bacterial Pathogens <i>Neisseria Meningitidis</i> and <i>Neisseria Gonorrhoeae</i> ," <i>Journal of Biological Chemistry</i> , Vol. 271, No. 45, pp. 28271-28276, The American Society for Biochemistry and Molecular Biology, Inc., USA, (November 8, 1996)	
	AN	GILBERT, et al., "Biosynthesis of Ganglioside Mimics in <i>Campylobacter Jejuni</i> OH4384," <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 6, pp. 3896-3906, The American Society for Biochemistry and Molecular Biology, Inc., USA, (February 11, 2000)	
	AO	ITO et al., "Synthesis of Bioactive Sialosides" <i>Pure Appl. Chem.</i> , 65: 753 (1993)	
	AP	KUROKI, "Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 Contain β-N-Acetylglucosamine Residues" <i>Ann. Neurol.</i> , 33: 243-247 (1993)	
	AQ	PARKHILL, et al. "The Genome Sequence of the Food-Borne Pathogen <i>Campylobacter Jejuni</i> Reveals Hypervariable Sequences," <i>Nature</i> , Vol. 403, pp. 665-668, (February 10, 2000)	
	AR	PENNER, et al., "Diversity of Lipopolysaccharide Structures in <i>Campylobacter Jejuni</i> ," <i>The Journal of Infectious Diseases</i> , Vol. 176, No. 2, pp. S135-S138, (December 1997)	
	AS	PRENDERGAST, et al., "Lipopolysaccharides from <i>Campylobacter Jejuni</i> O:41 Strains Associated with Guillain-Barré Syndrome Exhibit Mimicry of GM1 Ganglioside," <i>Infection and Immunity</i> , Vol. 68, No. 8, pp. 3649-3677, (August 1998)	
	AT	PRESTON, et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," <i>Critical Reviews in Microbiology</i> , Vol. 22, No. 3, pp. 139-180, (1996)	
	AU	SABESAN et al., "Combined Chemical and Enzymatic Synthesis of Sialyloligosaccharides and Characterization by 500-MHz ¹ H and C NMR Spectroscopy" <i>J. Am. Chem. Soc.</i> , 108: 2068-2080 (1986)	
	AV	SALLOWAY, et al., "Miller-Fisher Syndrome Associated with <i>Campylobacter Jejuni</i> Bearing Lipopolysaccharide Molecules that Mimic Human Ganglioside GD3," <i>Infection and Immunity</i> , Vol. 64, No. 8, pp. 2845-2849, (August 1996)	
	AW	WAKARCHUK et al., "Functional Relationships of the Genetic Locus Encoding the Glycosyltransferase Enzymes Involved in Expression of the Lacto-N-neotetraose Terminal Lipopolysaccharide Structure in <i>Neisseria meningitidis</i> " <i>J. Biol. Chem.</i> , 271: 19166-19173 (1996)	
D	AX	WOOD, et al., "Cloning, Mutation and Distribution of a Putative Lipopolysaccharide Biosynthesis Locus in <i>Campylobacter Jejuni</i> ," <i>Microbiology</i> , Vol. 145, No. 2, pp. 379-388, (February 1999)	

Examiner Signature	 SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER	Date Considered	040700
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1404050 v1

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/01B (10-01)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Compl to If Kn wn

Application Number	10/303,128
Filing Date	November 21, 2002
First Named Inventor	Gilbert, Michel, et. al.
Art Unit	1652
Examiner Name	Unassigned
Attorney Docket Number	018633-000112US

FOREIGN PATENT DOCUMENTS

[illegible]

RECEIVED
MAR 07 2003
TECH CENTER 1600/2900

**Examiner
Signature**

Date Considered

1	16	04
---	----	----

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

SF 1436768 v1